Correlation Between Defence Therapeutics and Marizyme

Can any of the company-specific risk be diversified away by investing in both Defence Therapeutics and Marizyme at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Defence Therapeutics and Marizyme into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Defence Therapeutics and Marizyme, you can compare the effects of market volatilities on Defence Therapeutics and Marizyme and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Defence Therapeutics with a short position of Marizyme. Check out your portfolio center. Please also check ongoing floating volatility patterns of Defence Therapeutics and Marizyme.

Diversification Opportunities for Defence Therapeutics and Marizyme

0.19

Correlation Coefficient

Defence Therapeutics  Marizyme

Average diversification

The 3 months correlation between Defence and Marizyme is 0.19. Overlapping area represents the amount of risk that can be diversified away by holding Defence Therapeutics and Marizyme in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Marizyme and Defence Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Defence Therapeutics are associated (or correlated) with Marizyme. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Marizyme has no effect on the direction of Defence Therapeutics i.e., Defence Therapeutics and Marizyme go up and down completely randomly.

Pair Corralation between Defence Therapeutics and Marizyme

Assuming the 90 days horizon Defence Therapeutics is expected to under-perform the Marizyme. But the otc stock apears to be less risky and, when comparing its historical volatility, Defence Therapeutics is 6.2 times less risky than Marizyme. The otc stock trades about -0.05 of its potential returns per unit of risk. The Marizyme is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  4.00  in Marizyme on September 12, 2024 and sell it today you would lose (1.00) from holding Marizyme or give up 25.0% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	98.44%
Values	Daily Returns

Defence Therapeutics  vs.  Marizyme

Defence Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Defence Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's technical and fundamental indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.

Marizyme

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Marizyme are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady basic indicators, Marizyme displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Defence Therapeutics and Marizyme

The main advantage of trading using opposite Defence Therapeutics and Marizyme positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Defence Therapeutics position performs unexpectedly, Marizyme can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marizyme will offset losses from the drop in Marizyme's long position.

The idea behind Defence Therapeutics and Marizyme pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.